Side-by-side research comparison of IGF-1 and MK-677 across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 14 head-to-head studies plus 62 on IGF-1 and 57 on MK-677.
| IGF-1 | MK-677 | |
|---|---|---|
| Drug class | growth factor | n/a |
| Studies in corpus | 62 | 57 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | cohort · 3 rct · 20 other · 15 case series · 1 case report · 1 preclinical animal · 9 review · 2 in vitro · 2 | rct · 10 other · 10 review · 5 preclinical animal · 20 in vitro · 4 case report · 1 |
| Studies with explicit sample size | 16 | 8 |
| Head-to-head studies in corpus | 14 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real IGF-1 and MK-677 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 17 IGF-1 batches across 10 manufacturers, 99.17% avg purity.
We tested 68 MK-677 batches across 31 manufacturers, 98.6% avg purity.
We hold deeper lab coverage on MK-677 (68 batches tested). IGF-1 edges ahead on average measured purity (99.17% vs 98.6%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both IGF-1 and MK-677 — the gold-standard direct comparison evidence.
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wasting. For clinicians and researchers, t…
**Femoral neck fracture is among the most clinically consequential osteoporotic injuries**, making even a modest site-specific BMD advantage potentially meaningful for fracture prevention — the combination's **+1.7 percentage-point femoral neck benefit** is…
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension of sarcopenia without requiring injection…
**Clinicians and advanced users should note the transient nature of leptin elevation** — an effect that normalizes by 8 weeks — which suggests early adaptation in the `leptin` signaling axis and argues against long-term adipokine disruption from MK-677. The…
**Elevated IGF-1 alone does not translate to clinically meaningful functional recovery** in frail elderly hip fracture patients — a finding that should temper enthusiasm for `GHSR` agonists in this population. The emergence of a **congestive heart failure s…
If the trial yielded positive results, this study would validate an oral therapeutic approach for fibromyalgia, potentially offering a more convenient and accessible alternative to injectable growth hormone. An effective oral treatment could significantly i…
**The 84% IGF-1 elevation confirms MK-0677 reliably engages its target even in elderly, post-surgical patients** — a pharmacokinetically important signal for clinicians and researchers designing GH-axis interventions. However, the disconnect between robust …
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the body's own GH release, offers a promising…
These findings highlight a significant challenge for the long-term use of oral GHSs like MK-677 for growth promotion. While the compound can acutely stimulate a robust GH pulse, the body appears to develop a powerful counter-regulatory response that neutral…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rather than bypassing it. The key clinical in…
Looking for vendor-level purity, endotoxin, and HPLC data on IGF-1 or MK-677? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.